Compare UFI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | RNTX |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 80.7M |
| IPO Year | 1994 | N/A |
| Metric | UFI | RNTX |
|---|---|---|
| Price | $4.62 | $1.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 73.7K | ★ 591.2K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $571,344,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $0.85 |
| 52 Week High | $5.30 | $2.18 |
| Indicator | UFI | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.32 | 48.28 |
| Support Level | $4.29 | $0.99 |
| Resistance Level | $4.74 | $1.33 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 89.04 | 70.95 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.